Finoriq research workspace
Xencor Inc (XNCR) SEC Filings & Filing Highlights
Xencor Inc provides Ultomiris to treat patients with atypical hemolytic uremic syndrome. Review XNCR SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
- Company
- Xencor Inc (XNCR)
- Ticker
- XNCR
- Market Cap
- $1.4B
- Latest Price
- $18.81
- Industry
- Biotech & Pharma
Xencor Inc (XNCR) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Xencor Inc (XNCR).
| Event | Form | Date |
|---|---|---|
| On June 16, 2026, Xencor, Inc. held its 2026 Annual Meeting of Stockholders. A total of 63,939,...On June 16, 2026, Xencor, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders. A total of 63,939,410 shares of the Company’s... | 8-K5.07 | 2026-06-18 |
| Xencor Inc: Earnings or resultsOn May 6, 2026, Xencor, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026 in the press releas... | 8-K2.02 | 2026-05-06 |
| Xencor, Inc. held a conference call on May 5, 2026 to discuss XmAb942 and XmAb412 data presenta...Xencor, Inc. (the “Company”) held a conference call on May 5, 2026 to discuss XmAb942 and XmAb412 data presentations at the Digestive Disea... | 8-K7.01 | 2026-05-05 |
| On April 23, 2026, Xencor, Inc. (the “Company”) adopted the Xencor, Inc. Executive Severance Po...On April 23, 2026, Xencor, Inc. (the “Company”) adopted the Xencor, Inc. Executive Severance Policy (the “Severance Policy”), pursuant to w... | 8-K5.02 | 2026-04-27 |
| Date: March 9, 2026On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreem... | 8-K1.02 | 2026-03-09 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.